Alpha-synuclein kinase
AssigneeElan Pharma International Limited
InventorsTami J. Chilcote, Kelly Banducci, Normand L. Frigon, Jr., Guriqbal S. Basi, John P. Anderson, Jason Goldstein, Irene Griswold-Prenner, David Chereau
Life of this patent
Estimating the term…
Abstract
The invention provides agents and methods for treatment of diseases associated with Lewy body diseases (LBDs) in the brain of a patient. Preferred agents include inhibitors of PLK2 and GRK6 kinases.
Claims7
A method for producing alpha-synuclein phosphorylated at serine 129 comprising:
- providing a plasmid encoding alpha-synuclein and a plasmid encoding PLK2 in a bacterial cell;
- culturing the cell whereby the plasmids are co-expressed to produce alpha-synuclein and PLK2 in the cell, whereby the PLK2 phosphorylates the alpha-synuclein in the cell;
- and
- isolating alpha-synuclein from the cell, wherein the isolated alpha-synuclein comprises alpha-synuclein phosphorylated at serine 129.
A method for producing human synuclein phosphorylated at serine 129 comprising co-expressing recombinant human alpha-synuclein and recombinant human PLK2 in a bacterial cell under conditions in which at least a portion of the expressed alpha-synuclein is phosphorylated at serine-129.
Dependencies are inferred from the claim text.